

## PRESS RELEASE

### **Gradientech appoints new Sales Manager for Central Europe**

*Uppsala, Sweden, March 28, 2025. The diagnostics company Gradientech today announces the appointment of Mark Lischeid as the company's new Sales Manager for Central Europe. Mark has extensive knowledge from strategic sales and commercial organisations, with over 25 years of experience in the diagnostic sector.*

In his role, Mark Lischeid will be responsible for driving regional sales growth, strengthening customer relationships, and expanding the company's presence in key markets across Central Europe. Mark has previously held key positions within key account management and strategic sales at Biocartis N.V., Philips GmbH, Institut Virion\Serion GmbH, among others.

"We're very pleased to welcome Mark Lischeid to the Gradientech team. With his proven track record of driving sales success and building strong relationships with partners and clients, he is well-positioned to support Gradientech's mission and strategic goals. Mark will play a vital role in further strengthening our market position in Central Europe," says AnnaLotta Schiller, Chief Commercial Officer at Gradientech.

"I am thrilled to join Gradientech and embark on this exciting journey with the QuickMIC® system, which addresses important clinical needs in clinical diagnostics through its speed and precision, holding promise for taking antibiotic susceptibility testing to the next level. I look forward to driving new opportunities in the region and working closely with our customers and drive growth and success in this dynamic area," says Mark Lischeid, Sales Manager Central Europe at Gradientech.

*The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for diagnostic use in the United States.*

#### **For further information, please contact:**

Dr Sara Thorslund, CEO

Tel: +46 736 29 35 80

[sara.thorslund@gradientech.se](mailto:sara.thorslund@gradientech.se)

Dr AnnaLotta Schiller, CCO

Tel: +46 733 42 32 93

[annalotta.schiller@gradientech.se](mailto:annalotta.schiller@gradientech.se)

#### **About Gradientech**

*Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [www.gradientech.se](http://www.gradientech.se) for more information.*